中文别名 |
度鲁特韦 GMP;德罗特韦(GSK-1349572,DTG);度鲁特韦;(4R,12AS)-N-[(2,4-二氟苯基)甲基]-3,4,6,8,12,12A-六氢-7-羟基-4-甲基-6,8-二氧代-2H-吡啶并[1',2'4,5]吡嗪并[2,1-B][1,3]嗪-9-甲酰;Dolutegravir标准品;德罗特韦;德罗特韦 GSK-1349572;度鲁特维游离酸;(4R,12aS)-N-[(2,4-二氟苯基)甲基]-3,4,6,8,12,12a-六氢-7-羟基-4-甲基-6,8-二氧代-2H-吡啶并[1',2':4,5]吡嗪并[2,1-b][1,3]噁嗪-9-甲酰胺;多替拉韦;杜鲁特韦;多特格伟;度鲁特韦游离酸;杜鲁特韦,德罗特韦;德罗特韦 GSK1349572;DOLUTEGRAVIR 度鲁特韦;多替拉韦杂质1 |
英文别名 |
GSK1349572;(4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide;Dolutegravir;Dolutegravir (GSK1349572);Dolutegravir-D5;GSK-1349572;Tivicay;(4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide;Dolutegravi;Dolutegravir API;Dolutegravir free acid;GSK1349572(dolutegravir);GSK1349572 (GSK1349572);Dolutegravir Impurity 1;MLS006011137;Dolutegravir [USAN];Q937224;DOLUTEGRAVIR [INN];CCG-268876;J-501471;(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0(3),?]tetradeca-10,13-diene-13-carboxamide;3s3m;(4R,12aS)-N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide;Soltegravir;Dolutegravir (USAN);AS-75277;J05AX12;Dolutegravir (0.1 mg/mL in Methanol);2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS);DKO1W9H7M1;(4R,12.ALPHA.S)-N-((2,4-DIFLUOROPHENYL)METHYL)-7-HYDROXY-4-METHYL-6,8-DIOXO-3,4,6,8,12,12.ALPHA.-HEXAHYDRO-2H-PYRIDO(1',2':4,5)PYRAZINO(2,1-.BETA.)(1,3)OXAZINE-9-CARBOXAMIDE;Z2235801952;(4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide;AKOS025396657;(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0,3,8]tetradeca-10,13-diene-13-carboxamide;S/GSK1349572,GSK1349572;HY-13238;NCGC00346629-01;DOLUTEGRAVIR [WHO-DD];MFCD20488027;(4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid-2,4 difluorobenzylamide;Dolutegravir [USAN:INN];SCHEMBL82071;1051375-16-6 (free);(4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxamide;CHEBI:76010;AC-28371;NCGC00346629-02;DTXSID90909356;BCP9000620;EN300-7409916;RHWKPHLQXYSBKR-BMIGLBTASA-N;(4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1 ,3]oxazine-9-carboxamide;(4R,12alphaS)-N-((2,4-DIFLUOROPHENYL)METHYL)-7-HYDROXY-4-METHYL-6,8-DIOXO-3,4,6,8,12,12alpha-HEXAHYDRO-2H-PYRIDO(1',2':4,5)PYRAZINO(2,1-beta)(1,3)OXAZINE-9-CARBOXAMIDE;D10066;s2667;S/GSK-1349572;Dolutegravir DTG;DB08930;UNII-DKO1W9H7M1;1051375-16-6;EX-A1695;CS-0454;Dolutegravir?;(4R,12aS)-N-;CHEMBL1229211;GTPL7365;(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide;(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diaz... |